Certain Nasal Devices and Components Thereof; Notice of Institution of Investigation, 13781-13782 [2025-05116]
Download as PDF
Federal Register / Vol. 90, No. 57 / Wednesday, March 26, 2025 / Notices
Issued: March 21, 2025.
Sharon Bellamy,
Supervisory Hearings and Information
Officer.
by accessing its internet server at
https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
[FR Doc. 2025–05114 Filed 3–25–25; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1444]
Certain Nasal Devices and
Components Thereof; Notice of
Institution of Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
February 18, 2025, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Aardvark Medical Inc. of
Denton, Texas. A supplement was filed
on February 25, 2025. The complaint, as
supplemented, alleges violations of
section 337 based upon the importation
into the United States, the sale for
importation, and the sale within the
United States after importation of
certain nasal devices and components
thereof by reason of the infringement of
certain claims of U.S. Patent No.
9,750,856 (‘‘the ’856 patent’’); U.S.
Patent No. 11,318,234 (‘‘the ’234
patent’’); U.S. Patent No. 11,883,009
(‘‘the ’009 patent’’); U.S. Patent No.
11,883,010 (‘‘the ’010 patent’’); and U.S.
Patent No. 11,889,995 (‘‘the ’995
patent’’). The complaint, as
supplemented, further alleges that an
industry in the United States exists as
required by the applicable Federal
Statute. The complainant requests that
the Commission institute an
investigation and, after the
investigation, issue a limited exclusion
order and cease and desist orders.
ADDRESSES: The complaint, except for
any confidential information contained
therein, may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
khammond on DSK9W7S144PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:57 Mar 25, 2025
Jkt 265001
Susan Orndoff, The Office of Docket
Services, U.S. International Trade
Commission, telephone (202) 205–1802.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2024).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
March 20, 2025, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products
identified in paragraph (2) by reason of
infringement of one or more of claims
1–5, 7–14, and 16–19 of the ’856 patent;
claims 1–4, 6, 8–12, 14–17, 21–24, 27,
and 28 of the ’234 patent; 1–3, 6–8, 10–
12, 16–18, 21, 22, and 28 of the ’009
patent; claims 1–8, 10–15, and 17–22 of
the ’010 patent; and claims 1–9, 12–21,
23, 24, and 26 of the ’995 patent, and
whether an industry in the United
States exists as required by subsection
(a)(2) of section 337;
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is ‘‘nasal irrigation and
aspiration devices and components
thereof’’; 1
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
The complainant is:
Aardvark Medical Inc., 204 Cardinal
Drive, Denton, Texas 76209
1 In this plain English statement of the scope of
investigation, ‘‘components thereof’’ is included
pursuant to the allegations in the complaint. To the
extent that the Complainant has included such an
allegation based upon a concern regarding specific
components, the Complainant should, during the
course of this investigation, seek adjudication and
specifically identify the components of the claimed
invention sought for exclusion. The lack of
adjudication of specific components, however,
would not affect any later ability to adjudicate and
remedy circumvention through the importation of
components with additional enforcement actions.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
13781
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Xiamenximier Electronic Commerce
Co., Ltd (d/b/a Cenny), Room 203,
Building 1070–2, Caitangshe, Huli
District, Xiamen City, Fujian China
361000
Xia Men Deng Jia E-Commerce Co., Ltd.,
(d/b/a Ronfnea), Room 101, No. 1070–
1, Caitangshe, Xiamen, Huli District,
Fujian, China 361006, Chongqing
Moffy Innovation Technology, Co.,
Ltd., No. 292, Jingdongfang Rd.,
Beibei Dist., Chongqing City, 400714
China
Guangdong XINRUNTAO Technology,
Co., Ltd., Room 1101–1102, Xingji
Tower, Xinqiao, Bao’an Shenzhen,
Guangdong, China
Shenzhen Jun&Liang Media Tech
Limited, Building 16, Dongcai
Industrial Park, Gushu Village,
Xixiang Town, Bao’an District,
Shenzhen, China 518102
RhinoSystems, Inc., 1 American Road,
Suite 1100, Brooklyn, Ohio 44144
Spa Sciences LP, 584 NW University
Blvd., Suite 600, Port St. Lucie,
Florida 34986
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
The Office of Unfair Import
Investigations will not participate as a
party in this investigation.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
E:\FR\FM\26MRN1.SGM
26MRN1
13782
Federal Register / Vol. 90, No. 57 / Wednesday, March 26, 2025 / Notices
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: March 21, 2025.
Sharon Bellamy,
Supervisory Hearings and Information
Officer.
[FR Doc. 2025–05116 Filed 3–25–25; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on February 11, 2025,
Pharmaron Manufacturing Services (US)
LLC, 498 Washington Street, Coventry,
Rhode Island 02816, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
[Docket No. DEA–1514]
Importer of Controlled Substances
Application: Pharmaron Manufacturing
Services (US) LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Pharmaron Manufacturing
Services (US) LLC has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
listed below for further drug
information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before April 25, 2025. Such
persons may also file a written request
for a hearing on the application on or
before April 25, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
khammond on DSK9W7S144PROD with NOTICES
DATES:
VerDate Sep<11>2014
16:57 Mar 25, 2025
Jkt 265001
Controlled substance
Dimethyltryptamine ..........
Drug
code
Schedule
7435
I
The company plans to import the
above controlled substance for internal
analytical use and to support technology
transfer, further process, and subsequent
production of Active Pharmaceutical
Ingredient for sale to its customers. No
other activity for this drug code is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025–05056 Filed 3–25–25; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1512]
Bulk Manufacturer of Controlled
Substances Application: Pharmaron
Manufacturing Services (US), LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
electronic comments on or objections to
the issuance of the proposed registration
on or before May 27, 2025. Such persons
may also file a written request for a
hearing on the application on or before
May 27, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on February 11, 2025,
Pharmaron Manufacturing Services
(US), LLC, 498 Washington Street,
Coventry, Rhode Island 02816 applied
to be registered as a bulk manufacturer
of the following basic class(es) of
controlled substance(s):
Controlled substance
Dimethyltryptamine ....
Oxymorphone ............
Noroxymorphone .......
Drug
code
7435
9652
9668
Schedule
I
II
II
The company plans to bulk
manufacture the listed controlled
substances to produce material for
clinical trials. No other activities for
these drug codes are authorized for this
registration.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025–05055 Filed 3–25–25; 8:45 am]
BILLING CODE P
AGENCY:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Pharmaron Manufacturing
Services (US), LLC has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
SUMMARY:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
[Docket No. DEA–1515]
Bulk Manufacturer of Controlled
Substances Application: Sterling
Wisconsin, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
E:\FR\FM\26MRN1.SGM
26MRN1
Agencies
[Federal Register Volume 90, Number 57 (Wednesday, March 26, 2025)]
[Notices]
[Pages 13781-13782]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-05116]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1444]
Certain Nasal Devices and Components Thereof; Notice of
Institution of Investigation
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that a complaint was filed with the
U.S. International Trade Commission on February 18, 2025, under section
337 of the Tariff Act of 1930, as amended, on behalf of Aardvark
Medical Inc. of Denton, Texas. A supplement was filed on February 25,
2025. The complaint, as supplemented, alleges violations of section 337
based upon the importation into the United States, the sale for
importation, and the sale within the United States after importation of
certain nasal devices and components thereof by reason of the
infringement of certain claims of U.S. Patent No. 9,750,856 (``the '856
patent''); U.S. Patent No. 11,318,234 (``the '234 patent''); U.S.
Patent No. 11,883,009 (``the '009 patent''); U.S. Patent No. 11,883,010
(``the '010 patent''); and U.S. Patent No. 11,889,995 (``the '995
patent''). The complaint, as supplemented, further alleges that an
industry in the United States exists as required by the applicable
Federal Statute. The complainant requests that the Commission institute
an investigation and, after the investigation, issue a limited
exclusion order and cease and desist orders.
ADDRESSES: The complaint, except for any confidential information
contained therein, may be viewed on the Commission's electronic docket
(EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email
[email protected]. Hearing impaired individuals are advised that
information on this matter can be obtained by contacting the
Commission's TDD terminal on (202) 205-1810. Persons with mobility
impairments who will need special assistance in gaining access to the
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be
obtained by accessing its internet server at https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT: Susan Orndoff, The Office of Docket
Services, U.S. International Trade Commission, telephone (202) 205-
1802.
SUPPLEMENTARY INFORMATION:
Authority: The authority for institution of this investigation is
contained in section 337 of the Tariff Act of 1930, as amended, 19
U.S.C. 1337, and in section 210.10 of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10 (2024).
Scope of Investigation: Having considered the complaint, the U.S.
International Trade Commission, on March 20, 2025, ordered that--
(1) Pursuant to subsection (b) of section 337 of the Tariff Act of
1930, as amended, an investigation be instituted to determine whether
there is a violation of subsection (a)(1)(B) of section 337 in the
importation into the United States, the sale for importation, or the
sale within the United States after importation of certain products
identified in paragraph (2) by reason of infringement of one or more of
claims 1-5, 7-14, and 16-19 of the '856 patent; claims 1-4, 6, 8-12,
14-17, 21-24, 27, and 28 of the '234 patent; 1-3, 6-8, 10-12, 16-18,
21, 22, and 28 of the '009 patent; claims 1-8, 10-15, and 17-22 of the
'010 patent; and claims 1-9, 12-21, 23, 24, and 26 of the '995 patent,
and whether an industry in the United States exists as required by
subsection (a)(2) of section 337;
(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10(b)(1), the plain language
description of the accused products or category of accused products,
which defines the scope of the investigation, is ``nasal irrigation and
aspiration devices and components thereof''; \1\
---------------------------------------------------------------------------
\1\ In this plain English statement of the scope of
investigation, ``components thereof'' is included pursuant to the
allegations in the complaint. To the extent that the Complainant has
included such an allegation based upon a concern regarding specific
components, the Complainant should, during the course of this
investigation, seek adjudication and specifically identify the
components of the claimed invention sought for exclusion. The lack
of adjudication of specific components, however, would not affect
any later ability to adjudicate and remedy circumvention through the
importation of components with additional enforcement actions.
---------------------------------------------------------------------------
(3) For the purpose of the investigation so instituted, the
following are hereby named as parties upon which this notice of
investigation shall be served:
The complainant is:
Aardvark Medical Inc., 204 Cardinal Drive, Denton, Texas 76209
(b) The respondents are the following entities alleged to be in
violation of section 337, and are the parties upon which the complaint
is to be served:
Xiamenximier Electronic Commerce Co., Ltd (d/b/a Cenny), Room 203,
Building 1070-2, Caitangshe, Huli District, Xiamen City, Fujian China
361000
Xia Men Deng Jia E-Commerce Co., Ltd., (d/b/a Ronfnea), Room 101, No.
1070-1, Caitangshe, Xiamen, Huli District, Fujian, China 361006,
Chongqing Moffy Innovation Technology, Co., Ltd., No. 292, Jingdongfang
Rd., Beibei Dist., Chongqing City, 400714 China
Guangdong XINRUNTAO Technology, Co., Ltd., Room 1101-1102, Xingji
Tower, Xinqiao, Bao'an Shenzhen, Guangdong, China
Shenzhen Jun&Liang Media Tech Limited, Building 16, Dongcai Industrial
Park, Gushu Village, Xixiang Town, Bao'an District, Shenzhen, China
518102
RhinoSystems, Inc., 1 American Road, Suite 1100, Brooklyn, Ohio 44144
Spa Sciences LP, 584 NW University Blvd., Suite 600, Port St. Lucie,
Florida 34986
(4) For the investigation so instituted, the Chief Administrative
Law Judge, U.S. International Trade Commission, shall designate the
presiding Administrative Law Judge.
The Office of Unfair Import Investigations will not participate as
a party in this investigation.
Responses to the complaint and the notice of investigation must be
submitted by the named respondents in accordance with section 210.13 of
the Commission's Rules of Practice and Procedure, 19 CFR 210.13.
Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be
considered by the Commission if received not later than 20 days after
the date of service by the Commission of the complaint and the notice
of investigation. Extensions of time for submitting responses to the
complaint and the notice of investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely response to each
allegation in the complaint and in this notice may be deemed to
constitute a waiver of the right to appear and contest the allegations
of the complaint and this notice, and to authorize the administrative
law judge and the Commission, without further notice to the respondent,
to find the facts to be as alleged in the complaint and this notice and
to enter an initial determination and a final determination containing
[[Page 13782]]
such findings, and may result in the issuance of an exclusion order or
a cease and desist order or both directed against the respondent.
By order of the Commission.
Issued: March 21, 2025.
Sharon Bellamy,
Supervisory Hearings and Information Officer.
[FR Doc. 2025-05116 Filed 3-25-25; 8:45 am]
BILLING CODE 7020-02-P